Vir Biotechnology soars on Q4 results beat, Astellas collaboration
24/02/2026 10:42
** Shares of drug developer Vir Biotechnology VIR.O rise 65.2% at $12.28 premarket ** Co posts Q4 revenue of $64.1 mln, beating analyst est. of $23.1 mln; posts Q4 loss per share of 31 cents, compared with the consensus of loss of 49 cents - data compiled by LSEG ** Co highlights its agreement with Norgine and lower R&D expenses due to restructuring initiatives ** Co also plans to develop and commercialize its prostate cancer experimental drug with Japan's Astellas 4503.T ** As of last close, VIR stock up 23.2% YTD, following a 17.8% decline in 2025 (Reporting by Tharuniyaa Lakshmi in Bengaluru) ((tharuniyaa@thomsonreuters.com))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn